Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CD19-CAR-T cells · 1 trial · 1 indication
Percentage of participants with adverse events.
The percentage of participants who achieved complete remission (CR) and partial remission over all participants.
| Arm | Type | Description |
|---|---|---|
| CD19-CAR-T cells | EXPERIMENTAL | CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion. |
| Name | Type | Description |
|---|---|---|
| CD19-CAR-T cells | BIOLOGICAL | CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion. |
Inclusion Criteria: 1. Relapsed and refractory CD19 positive B-cell acute malignancies with: * Relapsed after competed remission, could not get competed remission after at more than 1 course of chemotherapy (including MRD≥0.1%); * MRD≥0.1% after allogeneic hematopoietic stem cell transplanta...